BIRC5 and cancer: Other therapeutic targets included the cancer-associated protein survivin, which is known to inhibit T cell activation in tumors, and the inhibitor of the Nod-like receptor family pyrin domain containing 3 (NLRP3), which is predominantly expressed in macrophages and contributes to their immunosuppressive function in tumors.